Brief: Acadia Pharmaceuticals Q2 EPS USD 0.16

Acadia Pharmaceuticals

06/08/2025 21:05

Overview

Acadia Q2 2025 revenue rises 9% year-over-year to $264.6 million

NUPLAZID sales up 7%, DAYBUE sales increase 14% year-over-year

Company raises low end of NUPLAZID sales guidance for 2025

Outlook

Acadia raises low end of NUPLAZID sales guidance to $665 to $690 million

Company expects total 2025 revenues (U.S. only) of $1.045 to $1.095 bln

Acadia anticipates DAYBUE sales of $380 mln to $405 mln

Top-line results for ACP-101 study expected early Q4 2025

Result Drivers

NUPLAZID SALES - Driven by strong commercial execution and increased engagement from direct-to-consumer campaigns

DAYBUE SALES - Growth attributed to increased unit sales and highest paid patient count to date

PATENT WINS - Secured market exclusivity for NUPLAZID through significant patent litigation victories

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$264.57 mln
Q2 EPS
$0.16
Q2 Net Income
$26.67 mln
Q2 Operating Expenses
$232.19 mln
Q2 Pretax Profit
$40.21 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc is $30.50, about 22.5% above its August 5 closing price of $23.64

The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nBw79RQgFa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)